Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.

导出 LinkOut

翻译打印收藏纠错

作者： Maura,Gasparetto ^[1] ; Shanshan,Pei ^[2] ; Mohammad,Minhajuddin ^[2] ; Brett,Stevens ^[2] ; Clayton A,Smith ^[2] ; Paul,Seligman ^[2]

作者单位： Division of Hematology, University of Colorado Medical Center, Aurora, CO, USA. Electronic address: Maura.Gasparetto@ucdenver.edu. ^[1] Division of Hematology, University of Colorado Medical Center, Aurora, CO, USA. ^[2]

关键词 AML Chemotherapy Ferroportin Iron

主题词抗代谢药, 抗肿瘤(Antimetabolites, Antineoplastic);阳离子转运蛋白质类(Cation Transport Proteins);细胞增殖(Cell Proliferation);阿糖胞苷(Cytarabine);细胞遗传学分析(Cytogenetic Analysis);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);预后(Prognosis);存活率(Survival Rate);肿瘤细胞, 培养的(Tumor Cells, Cultured)

DOI 10.1016/j.leukres.2019.02.011

PMID 30852438

发布时间 2020-05-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览16

Leukemia research

2019年80卷

1-10页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.

Leukemia research

相似文献

Leukemia research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.

Leukemia research

相似文献

Leukemia research

相关期刊

检索历史清除